Results 121 to 130 of about 48,541 (237)
Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1288-1297, May 2026.The European Medicines Regulatory Network plays a critical role in safeguarding public health through the assessment and supervision of human medicines. However, rapid scientific and technological advancements have exposed capability deficits across the network, threatening timely and effective regulatory decision‐making.
Naomi Beard +4 more
wiley +1 more source
The Journal of Pathology, Volume 269, Issue 1, Page 112-124, May 2026.Abstract Over recent years, several deep learning (DL) models have been presented to predict colorectal cancer (CRC) patient survival directly from haematoxylin and eosin (H&E)‐stained routine whole‐slide images (WSIs). Unlike traditional studies that rely on manually defined histopathological features, weakly supervised DL allows training directly on ...
Nic G Reitsam +23 more
wiley +1 more source
The Prostate, Volume 86, Issue 7, Page 800-804, May 15, 2026.ABSTRACT Background To compare choline PET‐CT and PSMA PET‐CT in a cohort of patients with high‐risk localized prostate cancer, assessing the diagnostic capacity of both tests. whose therapeutic approach could be modified based on the results. Methods An observational study was conducted in 116 patients with high‐risk prostate cancer between January ...
M. A. Tárraga‐Honrubia +5 more
wiley +1 more source
Evaluation of aptamers for targeted radiotherapy: Binding specificity and labelling with natural lutetium [PDF]
, 2012 Many cancer patients suffer from serious side effects when treated with external beam radiotherapy or chemotherapy because of damage to healthy tissues by lack of selectivity.
Gijs, Marlies
core
SUBDUE‐3: SUB‐urothelial DUrvalumab‐89zirconium injEction; a phase 0 biodistribution study protocol
BJU International, EarlyView.
Kevin G. Keane +9 more
wiley +1 more source
Clinical Physiology and Functional Imaging, Volume 46, Issue 3, May 2026.Abstract Introduction Aim Fibroblast activation protein inhibitor (FAPI) has demonstrated promising oncological diagnostic performance. Although no adverse events (AEs) have been previously reported, a formal safety evaluation of FAPI PET/CT is lacking.
Morten Bentestuen +8 more
wiley +1 more source
Equine Veterinary Education, Volume 38, Issue 5, Page e254-e263, May 2026.Summary Background Injury of the superficial digital flexor tendon (SDFT) branch is uncommon and the response to different treatments has not been reported. Objectives The aim of this study was to describe the clinical presentation, diagnostic features, treatment methods, and outcome of horses diagnosed with SDFT branch injuries.
P. Spiesshofer +3 more
wiley +1 more source